ArticleMolecular and cellular biochemistry2019
NGF protects bone marrow mesenchymal stem cells against 2,5-hexanedione-induced apoptosis in vitro via Akt/Bad signal pathway.
Article in Molecular and cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 18 citations in OpenAlex.
- TrkA activation sustains chemotherapy resistance in chemotolerant medulloblastoma cells.Acta neuropathologica communications · 2026Article
- Beyond conventional therapies: MSCs in the battle against nerve injury.Regenerative therapy · 2025Review
- Cracking the Code: The Role of Peripheral Nervous System Signaling in Fracture Repair.Current osteoporosis reports · 2024Review
- Regenerative capacity of trophoblast stem cell-derived extracellular vesicles on mesenchymal stem cells.Biomaterials research · 2023Article
- NGF/TrkA promotes the vitality, migration and adhesion of bone marrow stromal cells in hypoxia by regulating the Nrf2 pathway.Metabolic brain disease · 2022Article
- Nerve growth factor (NGF) and NGF receptors in mesenchymal stem/stromal cells: Impact on potential therapies.Stem cells translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Mesenchymal stem cell transplantation has been proposed as a promising therapy for regeneration of damaged tissues-especially, bone marrow mesenchymal stem cell (BMSC) transplantation therapy is considered to be an effective strategy for treating various injures in recent years. However, poor viability of transplanted BMSCs in injured tissues has limited their therapeutic efficiency. Nerve growth factor (NGF) has been reported to be a pro-survival factor in series of cells. Moreover, NGF could improve BMSC viability and activate anti-apoptotic pathway. Therefore, we are interested to know whether NGF promoted BMSC survival in transplanted tissue. In this study, we investigated the protective effect and potential mechanisms of NGF against apoptosis of BMSCs in vitro. 2,5-hexanedione (HD) was the apoptosis inducer. BMSCs were treated with 40 mM HD and different concentrations of NGF (0, 50, 100, 200 μg/L) together for 24 h. Results showed that NGF treatment increased the viability of BMSCs exposed to HD. Moreover, NGF effectively suppressed HD-induced apoptosis which was characterized by inhibiting caspase-3 activity, as well as mitochondrial transmembrane potential depolarization. Mechanistically, it was found that NGF promoted phosphorylation of Akt and Bad, which is TrkA dependent. However, K252a and MK-2206 (TrkA and Akt inhibitor, respectively) suppressed the anti-apoptosis of NGF, indicating the protective effect of NGF on BMSCs apoptosis via a novel Akt/Bad pathway. The findings suggested that NGF may be used as an effective protective agent against BMSC apoptosis so as to promote the survival rate of transplanted BMSCs and their tissue repair capability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.